PTC Therapeutics' EPS forecast was lowered, while PTC Inc.'s stock rose despite a "Hold" rating.

Investment firm Cantor Fitzgerald lowered its FY2025 EPS forecast for PTC Therapeutics to $8.20 but maintains an "Overweight" rating. Meanwhile, PTC Inc., a software provider, saw its stock holdings reduced by Unified Investment Management, with Q1 EPS at $1.79, exceeding estimates. PTC's stock rose 3.9% in the first quarter, with a market cap of $20.67 billion. Analysts rate PTC's stock as "Hold" with a consensus price target of $188.69.